Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure
- PMID: 29526139
- DOI: 10.1056/NEJMoa1800866
Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure
Abstract
Background: In an early analysis of this trial, use of a magnetically levitated centrifugal continuous-flow circulatory pump was found to improve clinical outcomes, as compared with a mechanical-bearing axial continuous-flow pump, at 6 months in patients with advanced heart failure.
Methods: In a randomized noninferiority and superiority trial, we compared the centrifugal-flow pump with the axial-flow pump in patients with advanced heart failure, irrespective of the intended goal of support (bridge to transplantation or destination therapy). The composite primary end point was survival at 2 years free of disabling stroke (with disabling stroke indicated by a modified Rankin score of >3; scores range from 0 to 6, with higher scores indicating more severe disability) or survival free of reoperation to replace or remove a malfunctioning device. The noninferiority margin for the risk difference (centrifugal-flow pump group minus axial-flow pump group) was -10 percentage points.
Results: Of 366 patients, 190 were assigned to the centrifugal-flow pump group and 176 to the axial-flow pump group. In the intention-to-treat population, the primary end point occurred in 151 patients (79.5%) in the centrifugal-flow pump group, as compared with 106 (60.2%) in the axial-flow pump group (absolute difference, 19.2 percentage points; 95% lower confidence boundary, 9.8 percentage points [P<0.001 for noninferiority]; hazard ratio, 0.46; 95% confidence interval [CI], 0.31 to 0.69 [P<0.001 for superiority]). Reoperation for pump malfunction was less frequent in the centrifugal-flow pump group than in the axial-flow pump group (3 patients [1.6%] vs. 30 patients [17.0%]; hazard ratio, 0.08; 95% CI, 0.03 to 0.27; P<0.001). The rates of death and disabling stroke were similar in the two groups, but the overall rate of stroke was lower in the centrifugal-flow pump group than in the axial-flow pump group (10.1% vs. 19.2%; hazard ratio, 0.47; 95% CI, 0.27 to 0.84, P=0.02).
Conclusions: In patients with advanced heart failure, a fully magnetically levitated centrifugal-flow pump was superior to a mechanical-bearing axial-flow pump with regard to survival free of disabling stroke or reoperation to replace or remove a malfunctioning device. (Funded by Abbott; MOMENTUM 3 ClinicalTrials.gov number, NCT02224755 .).
Comment in
-
A New Left Ventricular Assist Device - Better, but Still Not Ideal.N Engl J Med. 2018 Apr 12;378(15):1442-1443. doi: 10.1056/NEJMe1802639. N Engl J Med. 2018. PMID: 29641957 No abstract available.
-
The HeartMate 3 pump: Overcoming the hemocompatibility gap.J Thorac Cardiovasc Surg. 2018 Dec;156(6):2140-2142. doi: 10.1016/j.jtcvs.2018.05.055. Epub 2018 Jun 4. J Thorac Cardiovasc Surg. 2018. PMID: 30041926 No abstract available.
-
Magnetically Levitated Cardiac Pump at 2 Years.N Engl J Med. 2018 Aug 30;379(9):896-7. doi: 10.1056/NEJMc1809738. N Engl J Med. 2018. PMID: 30179390 No abstract available.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical